Basilea awarded additional CARB-X funding of USD6million to support the clinical development of antibiotic BAL2420
Funding is awarded following successful completion of IND-enabling studies and clinical study…
PIVOT-PO Phase 3 Data Show Tebipenem HBrs Potential as the First Oral Carbapenem Antibiotic for Patients with Complicated Urinary Tract Infections (cUTIs)
Data presented at IDWeek 2025 after study stopped early for efficacyPrimary endpoint…
